Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04415658 · ClinicalTrials.gov registry record · Phase 3
Intravenous Thyroxine for Heart-Eligible Organ Donors
A Phase 3 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 3
- Development phase
- 838
- Enrollment target
NCT04415658 is a Phase 3 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 838 participants.
The verdict
NCT04415658, a Phase 3 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 838 participants
- Enrollment target
Study Summary
This randomized controlled trial will evaluate whether intravenous thyroxine infusion given to brain-dead organ donors who are eligible to donate hearts for 12 hours will result in more hearts transplanted than saline placebo
Interventions
- DRUG Saline
- DRUG Thyroxine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 838 participants |
| Start Date | 2020-12-01 |
| Est. Completion | 2022-12-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04415658
The ClinicalTrials.gov registry entry for NCT04415658 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 838 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Saline is the first listed.
NCT04415658 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04415658 about?
NCT04415658 is a clinical study titled "Intravenous Thyroxine for Heart-Eligible Organ Donors". This randomized controlled trial will evaluate whether intravenous thyroxine infusion given to brain-dead organ donors who are eligible to donate hearts for 12 hours will result in more hearts transplanted than saline placebo
What is the current status of trial NCT04415658?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 838 participants. The study started on 2020-12-01. Estimated completion is 2022-12-06.
What interventions are being tested in trial NCT04415658?
The interventions under investigation include: Saline (DRUG), Thyroxine (DRUG).
Who is sponsoring clinical trial NCT04415658?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.